Mereo BioPharma Group plc (Mereo) (MREO) Social Stream



Mereo BioPharma Group plc (Mereo) (MREO): $2.61

0.04 (-1.51%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

F

Add MREO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#178 of 362

in industry

MEREO BIOPHARMA GROUP PLC (MREO) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering MEREO BIOPHARMA GROUP PLC.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-06-25 1 $10 $8 $9 $2.82 219.15%
2022-04-01 2 $8 $8 $8 $2.82 183.69%
2022-06-06 2 $8 $5 $6.5 $2.82 130.5%
2022-08-12 3 $8 $4 $5.666 $2.82 100.92%
2023-09-08 3 $5 $4 $4.333 $2.82 53.65%
2023-12-15 4 $5 $4 $4.25 $2.82 50.71%

The Trend in the Analyst Price Target


MREO's average price target has moved down $0 over the prior 63 days.

MREO reports an average of 218.94% for its upside potential over the past 37 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-07-11 3 5 4 4.333 1.28 238.52%
2023-09-08 3 5 4 4.333 1.41 207.3%
2023-10-13 4 5 4 4.250 1.29 229.46%
2023-12-05 4 5 4 4.250 2.03 109.36%
2023-12-15 4 5 4 4.250 2.05 107.32%

MREO Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.25 3 1 0 0 0 4

The Trend in the Broker Recommendations


MREO's average broker recommendation rating improved by 0.08 over the prior 39 weeks.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for MREO as an investment opportunity.

  • In the context of all US stocks, MEREO BIOPHARMA GROUP PLC's number of analysts covering the stock is greater than 57.17% of them.
  • In terms of how MEREO BIOPHARMA GROUP PLC fares relative to all US stocks, note that its average analyst price target is greater than 61.06% of that group.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, MEREO BIOPHARMA GROUP PLC's variance in analysts' estimates is lower than -66.37% of them.
  • In terms of how MEREO BIOPHARMA GROUP PLC fares relative to Healthcare stocks, note that its upside potential (average analyst target price relative to current price) is greater than 569.67% of that group.

Stocks similar to MEREO BIOPHARMA GROUP PLC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are GHSI, HOTH, and SXTC.

What is the outlook for MREO? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!